Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.

Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.

Rodin has gained $27 million as it plots clinical work on a new Alzheimer’s candidate next year.

In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective.

Sanofi and Lexicon aim to carve out a place for their experimental SGLT2/SGLT1 drug sotagliflozin in Type 1 diabetes.

The ear disease firm is laying off one-third of its noncommercial staff and hitting pause on its remaining pipeline programs.

Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.

The agreement positions Bristol-Myers to develop subcutaneous formulations of molecules against PD-1 and 10 other immuno-oncology targets.

R&D